FDA's Peripheral and Central Nervous System Drugs
Advisory Committee voted 25-0 that 0.5 mg/day of fingolimod from Novartis
AG (NYSE:NVS; SIX:NOVN) was effective at reducing the clinical
exacerbations of multiple sclerosis and concluded the safety data justified
approval of the small molecule to treat relapsing forms of MS. Nevertheless,
both the agency and the panel were concerned by safety signals